2 completed, 2 terminated, 1 active not recruiting, 1 not yet recruiting. 5 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 2, Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Not yet recruiting 1, Terminated 1 |
Follow Metastatic Synovial Sarcoma: new trials by email Literature Review of Metastatic Synovial Sarcoma trials Research Report on Metastatic Synovial Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Biopsy Procedure, Biospecimen Collection - Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 42 | 2026-11-23 | 2026-09-25 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-02-06 | 2026-11-04 |
| Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas Itacitinib, Laboratory Biomarker Analysis - Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 27 | 2019-09-30 | 2024-05-08 |
| Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab - Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 28 | 2017-12-14 | 2023-10-25 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 15 | 2017-07-14 | 2026-07-08 |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 16 | 2017-03-10 | 2023-08-16 |
| Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 151 | 2015-11-30 | 2022-08-23 |
Sarcoma, Synovial (7) · Histiocytoma, Malignant Fibrous (4) · Dermatofibrosarcoma (3) · Leiomyosarcoma (3) · Liposarcoma, Myxoid (3) · Sarcoma (3) · Liposarcoma (2) · Neurofibrosarcoma (2) · Chondrosarcoma (1) · Disorders of Sex Development (1) · Fallopian Tube Neoplasms (1) · Fibrosarcoma (1) · Hemangiosarcoma (1) · Melanoma (1) · Mycosis Fungoides (1)
Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms, Connective Tissue (7) · Neoplasms, Connective and Soft Tissue (7) · Neoplasms, Adipose Tissue (5) · Histiocytoma (4) · Neoplasms, Fibrous Tissue (4) · Sarcoma (4) · Liposarcoma (3) · Neoplasms, Muscle Tissue (3) · Neoplasms, Nerve Tissue (3) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Fibrosarcoma (2)
Biopsy (2) · Doxorubicin (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Cyclophosphamide (1) · Decitabine (1) · INCB039110 (1) · Injections (1) · Interferon-gamma (1) · Leukapheresis (1) · baricitinib (1) · interferon gamma-1b (1) · itacitinib (1) · liposomal doxorubicin (1) · pazopanib (1)
National Cancer Institute (NCI) (4) · Fred Hutchinson Cancer Center (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1)
United States (6)
Candace L Haddox (1) · Lara E Davis (1) · Lee Cranmer (1) · Michael S Khodadoust, MD (1) · Michael Wagner (1) · Philip McCarthy, MD (1) · William D Tap (1)
UM1CA186709 (2), P30CA015704 (1), P30CA016056 (1), R01CA164333 (1), U01CA154967 (1), U10CA180821 (1)